Business Context and Reporting Period
Relmada Therapeutics, Inc. (RLMD) filed a Form 8-K on November 4, 2025, to disclose regulatory feedback and clinical trial data for its lead candidate, NDV-01, a treatment for non-muscle invasive bladder cancer (NMIBC). The filing also includes preliminary, unaudited financial information as of September 30, 2025.
Key Financial Metrics
The filing provides only preliminary liquidity data and does not report revenue, profit, or operating margins.
- Cash and Equivalents: Approximately $13.9 million in cash, cash equivalents, and short-term investments as of September 30, 2025.
- Debt and Liquidity: No specific debt figures or liquidity ratios are provided in this filing.
- Revenue and Profit: Not reported in this document.
Material Changes and Clinical Updates
The primary material updates concern the development of NDV-01:
- FDA Feedback: The FDA indicated that a single-arm trial may be acceptable for BCG-unresponsive patients refractory to other therapies. Additionally, a randomized, post-TURBT adjuvant study comparing NDV-01 to observation in intermediate-risk NMIBC patients is generally acceptable, pending further design submission.
- Proposed Trials: The Company plans to request Type B meetings for two Phase III trials: a single-arm study enrolling approximately 100 patients and a randomized intermediate-risk trial enrolling approximately 266 patients.
- Safety Data: Nine-month data from a Phase II study of 36 patients showed no new safety signals. No patients experienced Grade 3 or higher treatment-related adverse events, and no patients discontinued due to adverse events. The most common adverse event was transient uncomfortable urination (62%).
- Efficacy Data: Complete Response (CR) rates were 92% anytime, 84% at 3 months, 87% at 6 months, and 85% at 9 months. No patients progressed to muscle-invasive disease or underwent radical cystectomy.
Outlook, Risks, and Management Commentary
Management intends to proceed with protocol development for the proposed Phase III trials based on FDA feedback. However, the filing explicitly states there can be no assurance that the FDA will agree that the new protocols are sufficient to support approval, nor that the Company can proceed on its proposed timetable. The preliminary financial data is unaudited and subject to material change upon completion of the quarter-end close.
Investor Verification Checklist
- Verify the final audited cash position for the quarter ended September 30, 2025, as the $13.9 million figure is preliminary.
- Confirm the outcome of the upcoming Type B meetings with the FDA regarding the Phase III trial designs.
- Monitor the enrollment progress and final results of the proposed single-arm and randomized Phase III trials.
- Review the full investor presentation (Exhibit 99.1) and press release (Exhibit 99.2) for detailed clinical data not summarized in the 8-K text.